High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils
Alexander EmmanuelliiD, Camilla SalvagnoiD, Sung‐Min HwangiD, Deepika AwasthiiD, Tito Alejandro SandovaliD, Chang-Suk ChaeiD, Jin‐Gyu CheongiD, Chen TaniD, Takao IwawakiiD, Juan R. Cubillos‐RuiziD
Abstract
High-grade serous ovarian cancer (HGSOC) is an aggressive malignancy that remains refractory to current immunotherapies. While advanced stage disease has been extensively studied, the cellular and molecular mechanisms that promote early immune escape in HGSOC remain largely unexplored. Here we report that primary HGSO tumors program neutrophils to inhibit T cell anti-tumor function by activating the endoplasmic reticulum (ER) stress sensor IRE1. We found that intratumoral neutrophils exhibited overactivation of ER stress response markers compared with their counterparts at non-tumor sites. Selective deletion of IRE1 in neutrophils delayed primary ovarian tumor growth and extended the survival of mice with HGSOC by enabling early T cell-mediated tumor control. Notably, loss of IRE1 in neutrophils sensitized tumor-bearing mice to PD-1 blockade, inducing HGSOC regression and long-term survival in [~]50% of treated hosts. Hence, neutrophil-intrinsic IRE1 facilitates early adaptive immune escape in HGSOC and targeting this ER stress sensor might be used to unleash endogenous and immunotherapy-elicited immunity that controls metastatic disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 24
- FWCI
- 4.25
- Field percentile
- top 4%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy
Boris J. N. Winterhoff, Nomeda Girnius, … Joan S. Brugge·bioRxiv·Jun 24, 2025
- Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer
Zhen Zeng, Anastasia Gandini, … Brian G. Gabrielli·British Journal of CancerPeer-reviewed·Apr 7, 2026
- Chemotherapy Induces an IL1β-dependent Neutrophil Recruitment that Promotes Chemoresistance in Metastatic Ovarian Cancer
Taito Miyamoto, Yujie Ye, … Nan Zhang·bioRxiv·Sep 21, 2025
- A TEMPORAL MODEL OF TUMOR-IMMUNE DYNAMICS IN HIGH GRADE SEROUS OVARIAN CANCER
Donagh Egan, Kate Glennon, … Donal J. Brennan·npj Precision OncologyPeer-reviewed·Jun 16, 2025
- High-Grade Serous Ovarian Tumor Cells Modulate NK Cell Function to Create an Immune-Tolerant Microenvironment
V. D. Gonzalez, Y.-W. Huang, … W. Fantl·bioRxiv·Nov 20, 2020
- Eliciting OTUD3/RIPK-Dependent Necroptosis to Prevent Epithelial Ovarian Cancer
J. Johnson, E. C. Bales, … Z. L. Watson·bioRxiv·Apr 29, 2020